



## **HRA Pharma signs agreement to acquire the Compeed® brand from CILAG GmbH International**

**Paris, France, July 27, 2017** – HRA Pharma, a fast-growing, innovative consumer healthcare company, announced today that it has signed an agreement with CILAG GmbH International to acquire global rights to Compeed®, a leading brand in blister care and lipcare treatments. The acquisition is expected to double the size of the existing HRA Pharma business and increase the strategic value of its consumer healthcare platform by creating a robust global consumer healthcare company with a strong European focus.

David Wright, HRA Pharma’s Chief Executive Officer, said: “This acquisition demonstrates HRA Pharma’s ability to execute on our ambitious growth strategy, in which we make selective acquisitions to expand our consumer healthcare portfolio and deliver high quality brands on a global scale. Compeed® is a well-established consumer healthcare brand that has consistently delivered strong revenues and growth. We are committed to further maximize the potential of this brand by leveraging our European commercial infrastructure, worldwide distribution network and strong brand-building capabilities.”

Recognised as a leading brand for European pharmacists, Compeed® provides consumers with a comprehensive portfolio of products for the relief and treatment of blisters, corns, calluses, cracked skin and cold sores.

Subject to certain closing conditions and regulatory approvals, the acquisition is expected to be completed within the third quarter of 2017. The terms of this agreement were not disclosed.

Moving forward, HRA Pharma’s ambition is to become one of the fastest growing global Consumer Healthcare companies, empowering people throughout the world to improve their lives by developing accessible, value added self-care solutions.

## **About HRA Pharma**

HRA Pharma is a fast growing, innovative consumer healthcare company, empowering people throughout the world to improve their lives by developing accessible, value added, self-care solutions. Historically centered on women's health, the company has become the European leader in emergency contraception. With ambitious projects in the pipeline, including innovative Rx-to-OTC switches, HRA Pharma is committed to bringing a range of innovative products and services to market, particularly in areas of unmet customer needs. Headquartered in Paris, France with subsidiaries across Western Europe and a global network of local partners covering over 90 countries, the company has a proven structure, the skills and experience to capture new consumer healthcare businesses and deliver high quality brands on a global scale. Visit [www.hra-pharma.com](http://www.hra-pharma.com) for more information.

###

## **Media contact**

Karina Bugnon

Tel - +33 (0) 1 40 33 11 30

Email – [k.bugnon@hra-pharma.com](mailto:k.bugnon@hra-pharma.com)